laurabbook@gmail.com

*August 2022* Alexander I. Spira, MD, PhD, FACP, research institute director, Thoracic and Phase 1 Trial Program, Virginia Cancer Specialists Research Institute, Virginia Cancer Specialists, clinical assistant professor, Johns Hopkins University, discusses additional studies investigating the use of lazertinib (Leclaza) and amivantamab-vmjw (Rybrevant) in EGFR-mutated non–small cell lung cancer (NSCLC).…

*August 2022* From WCLC Abstract presented by Dr. Jie Huang Introduction: Small cell lung cancer (SCLC) transformation remains one of the unsettled resistant mechanisms for lung adenocarcinoma (LUAD), of which co-occurring TP53 and RB1 mutations defined a subgroup of patients with increased risk of SCLC transformation. Our study aimed to…

*August 2022* A total of 77% of women with lung cancer surveyed reported moderate to severe sexual dysfunction, according to results of the SHAWL study presented at the World Conference on Lung Cancer. Of the 127 participants who noted sexual activity in the previous 30 days, 75 (59%) reported significant…

*August 2022* It’s a wrap! Catch up on key highlights of the IASLC 2022 World Conference on Lung Cancer with Dr. Narjust Florez and Dr. Stephen Liu as they discuss the science, social engagement and notable abstracts with Dr. Ben Levy. Listen here.

*September  2022* In this issue of the Journal of Thoracic Oncology, Piccirillo et al. report the results of the BEVERLY trial, a randomized phase 3 study that reveals the progression-free survival (PFS) benefit of bevacizumab to erlotinib as first-line treatment for Italian patients with metastatic NSCLC with common EGFR mutations. In this large study, after…

*August 2022* On August 11, 2022, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating human epidermal growth factor receptor 2 HER2 (ERBB2) mutations, as detected by an…